Bortezomib and Rituximab in De-Novo Adolescent/Adult CD20-Positive, Ph-Negative Pre B-Cell Acute Lymphoblastic Leukemia

Researchers conducted a Phase II study to test the activity of bortezomib and rituximab in combination with a pediatric-inspired regimen during induction therapy in newly diagnosed adolescents and adults with CD20-positive, Philadelphia (Ph)-negative precursor B-cell acute lymphoblastic leukemia.